Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor

The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism

(2010) Daniela Buglio et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy

(2010) Y. Wei et al.   CLINICAL CANCER RESEARCH

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors

(2010) Cliona Grant et al.   Expert Review of Anticancer Therapy

The Histone Deacetylase Inhibitor MGCD0103 Induces Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells through a Mitochondria-Mediated Caspase Activation Cascade

(2010) V. El-Khoury et al.   MOLECULAR CANCER THERAPEUTICS

The Histone Deacetylase Inhibitor MGCD0103 Has Both Deacetylase and Microtubule Inhibitory Activity

(2010) K. Chia et al.   MOLECULAR PHARMACOLOGY

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

(2009) Kristie A. Blum et al.   BRITISH JOURNAL OF HAEMATOLOGY

Histone deacetylase inhibitors as anti-neoplastic agents

(2009) Nicolas Batty et al.   CANCER LETTERS

The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation

(2009) Daniela Carlisi et al.   EUROPEAN JOURNAL OF CANCER

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

(2008) G. Garcia-Manero et al.   BLOOD

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

(2008) D. Buglio et al.   BLOOD

Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

(2008) C. Bonfils et al.   CLINICAL CANCER RESEARCH

Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor

(2008) Christophe Le Tourneau et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

(2008) Lillian L. Siu et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery ofN-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor

(2008) Nancy Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY